Last $62.65 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

csl ltd (CMXHF) Snapshot

Open
$62.65
Previous Close
$62.65
Day High
$62.65
Day Low
$62.65
52 Week High
11/7/13 - $66.00
52 Week Low
12/17/13 - $59.06
Market Cap
29.8B
Average Volume 10 Days
193.8
EPS TTM
--
Shares Outstanding
475.8M
EX-Date
03/5/14
P/E TM
--
Dividend
$1.13
Dividend Yield
1.73%
Current Stock Chart for CSL LTD (CMXHF)

Related News

No related news articles were found.

csl ltd (CMXHF) Related Businessweek News

No Related Businessweek News Found

csl ltd (CMXHF) Details

CSL Limited engages in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Switzerland, Germany, and internationally. The company operates through CSL Behring, bioCSL, and CSL Intellectual Property segments. The CSL Behring segment manufactures, markets, and develops plasma therapies, including plasma products and recombinants that are used to treat coagulation disorders, including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders, cardiac surgery, organ transplantation, and burn treatment, as well as to prevent hemolytic diseases in the newborn. The bioCSL segment manufactures and distributes non-plasma biotherapeutic products, including biological products for human use; vaccines to prevent viral and bacterial diseases; prescription pharmaceuticals to treat a range of human medical conditions; in vitro diagnostic products; and antivenoms to treat victims of venomous snake and spider bites. The CSL Intellectual Property segment engages in the commercialization of intellectual property. In addition, the company markets various vaccines and antivenoms, as well as a range of pharmaceutical products supplied by other manufacturers. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

11,285 Employees
Last Reported Date: 08/13/13
Founded in 1916

csl ltd (CMXHF) Top Compensated Officers

Chief Executive Officer, Managing Director, E...
Total Annual Compensation: $1.9M
Chief Financial Officer
Total Annual Compensation: $1.5M
Executive Vice President of Operations
Total Annual Compensation: $1.1M
Chief Scientific officer and Director of R&D
Total Annual Compensation: $1.2M
Executive Vice President of Legal, Group Gene...
Total Annual Compensation: $879.1K
Compensation as of Fiscal Year 2013.

csl ltd (CMXHF) Key Developments

CSL Limited Opens Biotechnology Manufacturing Facility in Melbourne, Australia

CSL Limited has opened the CSL Behring Biotechnology Manufacturing Facility in Melbourne, Australia. The new facility, located adjacent to the site's manufacturing plant for plasma products, is the centerpiece of CSL's $250 million expansion at its Broadmeadows site and will play an increasingly important role in the company's global operations, particularly in the late-stage development of new types of hemophilia products. It is most advanced facilities of its kind in the world and will produce novel recombinant therapies on a large scale for international clinical trials.

ASLAN Pharmaceuticals Pte., Ltd. Signs License Agreement with CSL Limited

ASLAN Pharmaceuticals Pte. Ltd. has signed a global license agreement with CSL Limited to develop CSL's anti-IL13 receptor monoclonal antibody, CSL334, currently in preclinical development for the treatment of asthma. Under the agreement, ASLAN will fund and develop CSL334 through to clinical proof of concept in a development program conducted primarily in Asia, targeting patients suffering moderate persistent to severe allergic asthma. CSL will be entitled to share returns generated by ASLAN from partnering the project.

CSL opens CSL Behring Biotechnology Manufacturing Facility

CSL has opened the CSL Behring Biotechnology Manufacturing Facility in Broadmeadows, Melbourne. The facility is located adjacent to CSL Behring's manufacturing plant for plasma products and is the centrepiece of the firm's USD 250 million expansion at its Broadmeadows site and is intended to play a major role in its global drug development strategy. The new plant will be utilised for producing novel recombinant therapies on a large scale for international clinical trials.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CMXHF:US $62.65 USD 0.00

CMXHF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,398 JPY -17.00
Biocon Ltd 465.10 INR -5.00
Green Cross Corp/South Korea 123,500 KRW +1,500
Grifols SA €32.68 EUR -1.14
Shire PLC 4,882 GBp -9.00
View Industry Companies
 

Industry Analysis

CMXHF

Industry Average

Valuation CMXHF Industry Range
Price/Earnings 25.1x
Price/Sales 6.1x
Price/Book 9.3x
Price/Cash Flow 24.3x
TEV/Sales 5.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CSL LTD, please visit www.csl.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.